Prothrombotic and Hemorrhagic Effects of Aspirin
Authors:
Open Access
- 3 July 2008
- journal article
- research article
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 15 (5) , 523-528
Abstract
Aspirin remains the most widely used drug for prevention of vascular events. Recent observational epidemiological evidence has raised the concern that aspirin withdrawal for treatment noncompliance, surgery, or side effects can carry an increased thrombotic risk. The delay to the thrombotic event was between 7 to 30 days in most reports and most frequently 7 to 10 days. The mechanism underlying this effect remains poorly understood. Using an in vivo model of laser-induced thrombosis, aspirin injected in 1 single dose of 100 mg/kg body weight has also shown a prothrombotic activity in the rat 8 to 10 days after injection in the normal rat. The hypothesis was made that minimal concentrations of aspirin or ultra-low dose aspirin (ULDA) could induce this effect. ULDA showed prothrombotic properties in the same model of induced thrombosis that were very similar to those described after aspirin withdrawal, but the effect was observed only 1 hour after aspirin administration. This prothrombotic effect of ULDA is very similar to the effect observed after COX 2 selective inhibition with NS 398. The administration of both the selective COX 2 inhibitor and ULDA did not produce further changes. In conclusion, the prothrombotic effects described in recent observational studies are likely produced by a direct effect of aspirin, whose putative mechanism involving COX 2 inhibition remains poorly understood.Keywords
This publication has 17 references indexed in Scilit:
- Reverse Effect of Aspirin: Is the Prothrombotic Effect after Aspirin Discontinuation Mediated by Cyclooxygenase 2 Inhibition?Pathophysiology of Haemostasis and Thrombosis, 2007
- Discontinuation of Perioperative Antiplatelet and Anticoagulant Therapy in Stroke PatientsNeurologic Clinics, 2006
- Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic EventsNew England Journal of Medicine, 2006
- A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50 279 patients at risk for coronary artery diseaseEuropean Heart Journal, 2006
- Low‐dose aspirin for secondary cardiovascular prevention – cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation – review and meta‐analysisJournal of Internal Medicine, 2005
- Coronary syndromes following aspirin withdrawalJACC, 2005
- Impact of Prior Use or Recent Withdrawal of Oral Antiplatelet Agents on Acute Coronary SyndromesCirculation, 2004
- Aspirin Withdrawal and Acute Lower Limb IschemiaAnesthesia & Analgesia, 2004
- Myocardial infarction after aspirin cessation in stable coronary artery disease patientsInternational Journal of Cardiology, 2000
- Thromboembolic Complications Several Days After a Single-Dose Administration of AspirinThrombosis Research, 1998